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Seeking Middle Ground 
 
Dear Dr. Nash, 
 
Your editorial, “Seeking Middle Ground” (December 2003), was right on the mark. 
Academia and the pharmaceutical industry share many common goals, chief among 
which are to effectively communicate scientific information and to improve the health 
status of patients. Bringing all key stakeholders to the table to work collaboratively is 
the best way to achieve these goals and to address these important and complicated 
issues. 
 
Jefferson should be commended for developing the Industry Advisory Council, a 
model that all medical academic institutions should emulate. 
 
Barry K. Herman, MD, MMM 
Director, Regional Medical and Research Specialist 
Psychiatry 
Pfizer, Inc. 
Radnor, PA 
 
* * * * *
Dear Dr. Nash, 
 
It is ironic that pens are considered to be unacceptably corrupting, yet 
pharmaceutical companies can pay hundreds of thousands of dollars for consulting or 
research and remain well within the AMA guidelines. Surely, if you believe that a 
physician will be influenced by a small gift, how much more is the plenary speaker or 
department chairman influenced by the company that pays for his or her fellow or 
funds their research? 
 
Likewise, if physicians can be swayed by a concert ticket, how much more will they 
have their behavior impacted to do unnecessary surgery or tests when they can 
generate a cash fee? The result of this dim view of physician behavior and morality 
has been a web of regulation and control. Our cash-strapped health care system 
spends more and more dollars on “supervision” and fewer dollars on patient care. 
Because of fear of even indirect pharmaceutical company influence, easy-to-spell and 
pronounce brand names are eschewed in favor of often confusing generic labels. 
 
The real answer is physician education, starting in medical school, about our deep, 
historical, unalterable obligation to our patients, and an environment where 
physicians are commended for assuming their rightful role as patient advocates 
rather than treated with suspicion or discounted as interchangeable providers that 
must constantly be watched lest they do too much or too little. Men and women go 
in harms way, into battle or burning buildings, because they think what they are  
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doing is right. Surely, educated physicians are no less susceptible than teenage 
soldiers to positive motivation to do the right thing. 
 
John R. Cohn, MD 
Clinical Professor of Medicine 
Clinical Assistant Professor of Pediatrics 
Jefferson Medical College 
 
* * * * *
Dear Dr. Nash, 
 
Why do you believe academe “needs” industry to help teach medicine to 
practitioners? I assume it's the money, and if so, tell me why innovative ways cannot 
be found to provide good quality CME much less expensively without industry 
participation. As I said in the JAMA piece last year, industry should not be prohibited 
from putting on its own “educational” programs, but why should they be accredited? 
 
What happens to our professional values, and to the public's opinion of our 
profession, when we allow industry to subsidize our accredited education? If industry 
were really willing to give totally unrestricted educational grants, without any 
involvement whatsoever, that might be defensible, but we know very well that most 
industry support would disappear. 
 
Does Jefferson make a profit from its CME collaborations with industry? Many (or 
most) schools do, and they ought to be ashamed. 
 
Arnold Relman, MD 
Professor Emeritus of Medicine and Social Medicine 
Harvard Medical School 
Editor-in-Chief Emeritus 
New England Journal of Medicine 
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